Lamisil and Sinus bradycardia - a phase IV clinical study of FDA data

Summary:

Sinus bradycardia is reported as a side effect among people who take Lamisil (terbinafine hydrochloride), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Vioxx, and have Joint pain.

The phase IV clinical study analyzes which people have Sinus bradycardia when taking Lamisil. It is created by eHealthMe based on reports of 13,455 people who have side effects when taking Lamisil from the FDA, and is updated regularly.

What is Lamisil?

Lamisil has active ingredients of terbinafine hydrochloride. It is often used in pulmonary aspergilloma (mycetoma). eHealthMe is studying from 14,080 Lamisil users. Check the latest studies of Lamisil.

What is Sinus bradycardia?

Sinus bradycardia (an unusually slow heartbeat due to heart disease) is found to be associated with 898 drugs and 1,055 conditions by eHealthMe. Check the latest studies of Sinus bradycardia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

13,455 people reported to have side effects when taking Lamisil.
Among them, 12 people (0.09%) have Sinus bradycardia.

Among these 12 people:

How long have people been on Lamisil when they have Sinus bradycardia? *

What is the gender of people who have Sinus bradycardia when taking Lamisil? *

female: 16.67 %
male: 83.33 %

What is the age of people who have Sinus bradycardia when taking Lamisil? *

What are other drugs people take besides Lamisil? *

What are other side effects people have besides Sinus bradycardia? *

Coronary Heart Disease (narrowing or blockage of the coronary arteries): 4 people, 33.33%
High Blood Pressure: 4 people, 33.33%
Arteriosclerosis Coronary Artery (thickening and hardening of arteries- coronary artery): 4 people, 33.33%
Tricuspid Valve Incompetence (inefficient heart valve): 4 people, 33.33%
Chest Pain: 4 people, 33.33%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 3 people, 25.00%
Non-Consummation: 3 people, 25.00%
Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 25.00%
High Density Lipoprotein Decreased: 3 people, 25.00%
High Blood Cholesterol: 3 people, 25.00%

What are the existing conditions these people have? *

Joint Pain: 3 people, 25.00%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 2 people, 16.67%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 8.33%
High Blood Pressure: 1 person, 8.33%
Dementia Alzheimer's Type (loss of mental ability with alzheimer's symptom): 1 person, 8.33%
Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Lamisil and have Sinus bradycardia?

- Check whether Sinus bradycardia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lamisil:

Lamisil (14,080 reports)

Browse all side effects of Lamisil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sinus bradycardia:

Sinus bradycardia (898 drugs)

Browse all the conditions that are associated with Sinus bradycardia:

Sinus bradycardia (1,055 conditions)

Related publications that referenced our studies

Yaylaci S, Kocayigit I, Genc A, Tamer A, Gunduz H, "Sinus bradycardia caused by flurbiprofen intoxication", Nigerian Journal of Cardiology, 2015 Jan .
Yaylaci S, Kocayigit I, Genc A, Tamer A, Gunduz H, "Sinus bradycardia caused by flurbiprofen intoxication", Nigerian Journal of Cardiology, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on terbinafine hydrochloride (the active ingredients of Lamisil) and Lamisil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.